Search Results - "GLIMM, H"

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment by Fan, F, Bashari, M H, Morelli, E, Tonon, G, Malvestiti, S, Vallet, S, Jarahian, M, Seckinger, A, Hose, D, Bakiri, L, Sun, C, Hu, Y, Ball, C R, Glimm, H, Sattler, M, Goldschmidt, H, Wagner, E F, Tassone, P, Jaeger, D, Podar, K

“…Despite therapeutic advances, multiple myeloma (MM) remains an incurable disease, predominantly because of the development of drug resistance. The activator…”
Get full text

Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling by Kordes, M, Röring, M, Heining, C, Braun, S, Hutter, B, Richter, D, Geörg, C, Scholl, C, Gröschel, S, Roth, W, Rosenwald, A, Geissinger, E, von Kalle, C, Jäger, D, Brors, B, Weichert, W, Grüllich, C, Glimm, H, Brummer, T, Fröhling, S

“…Activating BRAF mutations, in particular V600E/K, drive many cancers and are considered mutually exclusive with mutant RAS, whereas inactivating BRAF mutations…”
Get full text

High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma by Westphal, D., Garzarolli, M., Sergon, M., Horak, P., Hutter, B., Becker, J.C., Wiegel, M., Maczey, E., Blum, S., Grosche‐Schlee, S., Rütten, A., Ugurel, S., Stenzinger, A., Glimm, H., Aust, D., Baretton, G., Beissert, S., Fröhling, S., Redler, S., Surowy, H., Meier, F.

“…Summary Background Eccrine porocarcinoma (EPC) is a rare skin cancer arising from the eccrine sweat glands. Due to the lack of effective therapies, metastasis…”
Get full text

Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway by Maurus, K., Kosnopfel, C., Kneitz, H., Appenzeller, S., Schrama, D., Glutsch, V., Roth, S., Gerhard‐Hartmann, E., Rosenfeldt, M., Möhrmann, L., Fröhlich, M., Hübschmann, D., Stenzinger, A., Glimm, H., Fröhling, S., Goebeler, M., Rosenwald, A., Kutzner, H., Schilling, B.

“…Summary Background Epithelioid haemangioma (EH) arising from the skin is a benign vascular tumour with marked inflammatory cell infiltration, which exhibits a…”
Get full text

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794] by Hoffmann, K, Glimm, H, Radeleff, B, Richter, G, Heining, C, Schenkel, I, Zahlten-Hinguranage, A, Schirrmacher, P, Schmidt, J, Büchler, M W, Jaeger, D, von Kalle, C, Schemmer, P

“…Disease progression of hepatocellular cancer (HCC) in patients eligible for liver transplantation (LTx) occurs in up to 50% of patients, resulting in…”
Get full text

Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma by Dieter, S.M., Heining, C., Agaimy, A., Huebschmann, D., Bonekamp, D., Hutter, B., Ehrenberg, K.R., Fröhlich, M., Schlesner, M., Scholl, C., Schlemmer, H.-P., Wolf, S., Mavratzas, A., Jung, C.S., Gröschel, S., von Kalle, C., Eils, R., Brors, B., Penzel, R., Kriegsmann, M., Reuss, D.E., Schirmacher, P., Stenzinger, A., Federspil, P.A., Weichert, W., Glimm, H., Fröhling, S.

“…Sinonasal carcinomas (SNCs) comprise various rare tumor types that are characterized by marked histologic diversity and largely unknown molecular profiles, yet…”
Get full text

Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms by Apostolidis, L., Kreutzfeldt, S., Oles, M., Gieldon, L., Heining, C., Horak, P., Hutter, B., Fröhlich, M., Klink, B., Lamping, M., Uhrig, S., Stenzinger, A., Winkler, E.C., Wiedenmann, B., Jäger, D., Schröck, E., Keilholz, U., Pavel, M.E., Glimm, H., Fröhling, S.

Get full text

Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease by EISTERER, W, JIANG, X, AUEWARAKUL, C, BARNETT, M. J, EAVES, C. J, EAVES, A. C, CHRIST, O, GLIMM, H, LEE, K. H, PANG, E, LAMBIE, K, SHAW, G, HOLYOAKE, T. L, PETZER, A. L

“…Xenograft models of chronic phase human chronic myeloid leukemia (CML) have been difficult to develop because of the persistence of normal hematopoietic stem…”
Get full text

71: Targeted cancer genetics by Von Kalle, C, Fröhling, S, Glimm, H, Pfister, S.M, Zenz, T

Get full text

NDRG1 prognosticates the natural course of disease in WHO grade II glioma by Blaes, J., Weiler, M., Sahm, F., Hentschel, B., Osswald, M., Czabanka, M., Thomé, C. M., Schliesser, M. G., Pusch, S., Luger, S., Winkler, F., Radbruch, A., Jugold, M., Simon, M., Steinbach, J. P., Schackert, G., Tatagiba, M., Westphal, M., Tonn, J. C., Gramatzki, D., Pietsch, T., Hartmann, C., Glimm, H., Vajkoczy, P., von Deimling, A., Platten, M., Weller, M., Wick, W.

“…There is a lack of relevant prognostic and predictive factors in neurooncology besides mutation of isocitrate dehydrogenase 1 , codeletion of 1p/19q and…”
Get full text

Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer by Czink, E, Heining, C, Weber, T F, Lasitschka, F, Schemmer, P, Schirmacher, P, Weiss, K H, Glimm, H, Brors, B, Weichert, W, Jäger, D, Fröhling, S, Springfeld, C

“…Gallbladder cancer represents a rare but dismal disease. The only curative option is complete surgical resection, though patients often develop recurrent…”
Get more information

85 Wnt secretion is required to maintain Wnt activity in colon cancer by Voloshanenko, O, Erdmann, G, Dubash, T.D, Augustin, I, Metzig, M, Ball, C.R, Glimm, H, Spang, R, Boutros, M

Get full text

538: Wnt secretion is required to maintain Wnt activity in colon cancer by Voloshanenko, O, Erdmann, G, Dubash, T.D, Augustin, I, Metzig, M, Kerr, G, Ball, C.R, Glimm, H, Spang, R, Boutros, M

Get full text

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial by Heilig, C.E., Horak, P., Kreutzfeldt, S., Teleanu, V., Mock, A., Renner, M., Bhatti, I.A., Hutter, B., Hüllein, J., Fröhlich, M., Uhrig, S., Süße, H., Heiligenthal, L., Ochsenreither, S., Illert, A.L., Vogel, A., Desuki, A., Heinemann, V., Heidegger, S., Bitzer, M., Scheytt, M., Brors, B., Hübschmann, D., Baretton, G., Stenzinger, A., Steindorf, K., Benner, A., Jäger, D., Heining, C., Glimm, H., Fröhling, S., Schlenk, R.F.

“…Approvals of cancer therapeutics are primarily disease entity specific. Current molecular diagnostic approaches frequently identify actionable alterations in…”
Get full text

309: Clonal succession of transiently active TIC clones in human pancreatic cancer by Ball, C.R, Oppel, F, Ehrenberg, R, Weitz, J, Werner, J, Bergmann, F, Ishaque, N, Brors, B, Von Kalle, C, Glimm, H

Get full text

Direct evidence for multiple self-renewal divisions of human in vivo repopulating hematopoietic cells in short-term culture by GLIMM, H, EAVES, C. J

“…Recently, culture conditions that stimulate the proliferation of primitive hematopoietic cells defined by various phenotypic and functional endpoints in vitro…”
Get full text

Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up by Rückert, A, Glimm, H, Lübbert, M, Grüllich, C

“…An association of antiphospholipid antibody syndrome with antibodies directed against either phospholipids or plasma proteins strongly suggest that B-cell…”
Get full text

The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment by Fan, F, Vallet, S, Sattler, M, Tonon, G, Bashari, M.H, Bakiri, L, Jarahian, M, Roccaro, A, Ghobrial, I, Ball, C, Glimm, H, Anderson, K.C, Goldschmidt, H, Wagner, E.F, Jaeger, D, Podar, K

Get full text

What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion? by Sellner, L., Denzinger, S., Dietrich, S., Glimm, H., Merkel, O., Dreger, P., Zenz, T.

“…Chronic lymphocytic leukemia (CLL) with 17p deletion or mutations of the TP53 gene has a very poor outcome. Optimal treatment of these patients remains a major…”
Get full text

Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples by Schmidt, M, Hoffmann, G, Wissler, M, Lemke, N, Müssig, A, Glimm, H, Williams, D A, Ragg, S, Hesemann, C U, von Kalle, C

“…By identifying the sequence of retro- and lentiviral integration sites in peripheral blood leukocytes, the clonal composition and fate of genetically modified…”
Get more information